H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $40 from $45 and keeps a Buy rating on the shares. The firm ...

H.C. Wainwright lowered the firm’s price target on Vigil Neuroscience (VIGL) to $14 from $17 and keeps a Buy rating on the shares ahead of ...

AudioEye (NASDAQ:AEYE – Free Report) had its price target cut by HC Wainwright from $37.00 to $22.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy ...

Humacyte (NASDAQ:HUMA – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Fintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with ...

Shares of Core Scientific Inc. (CORZ) gained almost 8% in Tuesday’s regular session and extended gains during after-hours ...

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...

Ten companies across mixed sectors also mirrored a broader market optimism, booking modest gains during the end of the ...

H.C. Wainwright analyst Amit Dayal initiated coverage on Surf Air Mobility Inc. (NYSE:SRFM) with a Buy rating and price forecast of $12. The analyst writes that the company is positioned for a ...

Tuesday, Summit Therapeutics plc (NASDAQ:SMMT), currently trading at $18.84, maintained a Buy rating from H.C. Wainwright, with analysts keeping a steadfast $44.00 price target on the stock.

Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...